Philip E. Castle
National Cancer Institute, Division of Cancer Prevention
Dr. Philip E. Castle’s commendable journey in the medical field began in 2000 with the Division, under the guidance of Dr. Mark Schiffman. He secured a tenure-track position in 2003 and was granted tenure by 2010. In 2011, he ascended to the role of Executive Director and subsequently became the Chief Scientific Officer for ASCCP, previously recognized as the American Society for Colposcopy and Clinical Pathology. Before making his return to NCI in 2021, Dr. Castle was distinguished as a tenured professor in the Department of Epidemiology and Population Health at Albert Einstein College of Medicine. Moreover, he co-founded and served as the Executive Director for the Global Coalition Against Cervical Cancer. Presently, he is esteemed as a senior investigator in DCEG and helms the NCI’s Division of Cancer Prevention.
Globally, Dr. Castle is revered as a luminary in cervical cancer prevention. His groundbreaking work on HPV vaccinations, screening techniques, and insights into cervical precancer and cancer has left an indelible mark on the field. He played a crucial role in pioneering and authenticating novel technological solutions for cervical cancer prevention, including several HPV tests that garnered approval from the U.S. FDA. His relentless efforts and innovations have been pivotal in refining U.S. screening practices and management guidelines, particularly accentuating the role of primary HPV testing in diagnosing cervical cancer.